What are the best psychedelic stocks to buy?

The best psychedelic stocks have experimental psychedelic drugs already in clinical testing. They include Atai Life Sciences, Compass Pathways, Cybin, GH Research, and Mind Medicine.

Are psychedelic stocks a good investment?

Psychedelic stocks are risky. No company developing psychedelic drugs has obtained regulatory approvals or achieved profitability yet. These stocks would be unsuitable for many investors. However, certain psychedelic stocks could appeal to aggressive investors who aren't risk-averse.

What is the forecast for psychedelic stocks?

The psychedelic market is still in its early innings. However, with several psychedelic drugs making progress in clinical studies, the market could grow significantly over the next few years. Data Bridge Market Research projects that the global psychedelic market will increase by a compound annual growth rate of 13.3% through 2032 to about $8.3 billion. This bodes well for the stocks of top psychedelic drug companies.

Are psychedelic stocks legal to invest in?

Yes, psychedelic stocks are legal investment alternatives.

What drives growth in psychedelic stocks?

Several factors can contribute to the growth of psychedelic stocks. They include:Positive clinical trial resultsRegulatory approvalsMergers and acquisitionsIncreased interest from institutional investorsGreater public acceptance of psychedelic therapies

Is there an ETF for psychedelics?

Yes, there are some ETFs that own psychedelic stocks. The AdvisorShares Psychedelics ETF (NYSEMKT:PSIL) is the most prominent one.

Bars

Best Psychedelic Stocks to Buy in 2026 and How to Invest

Key Points

Psychedelic stocks focus on hallucinogenic treatments, carrying significant growth potential but high volatility.
Recent clinical trials show promise in treating depression and anxiety, boosting investment interest.
Investors can buy shares via brokerage accounts, weighing risks like clinical failures and regulatory hurdles.

Loading paragraph...

Ticker Information Table
Name and ticker	Market cap	Dividend yield	Industry
AtaiBeckley (NASDAQ:ATAI)	$1.7 billion	0.00%	Pharmaceuticals
Compass Pathways Plc (NASDAQ:CMPS)	$840.8 million	0.00%	Biotechnology
Cybin (NASDAQ:HELP)	$288.7 million	0.00%	Pharmaceuticals
Definium Therapeutics (NASDAQ:DFTX)	$2.3 billion	0.00%	Pharmaceuticals
GH Research (NASDAQ:GHRS)	$1.2 billion	0.00%	Pharmaceuticals

Data as of Apr 23, 2026. Showing 5 of 5 tickers.

Loading ticker_table...

Loading paragraph...

NASDAQ: ATAI

AtaiBeckley

Today's Change

(-3.29%) $-0.16

Current Price

$4.71

Key Data Points

Market Cap

$1.7B

Day's Range

$4.63 - $5.00

52wk Range

$1.29 - $6.75

Volume

4.5K

Avg Vol

5.6M

Loading company_card...

With prominent backing from venture capitalists, including billionaire Peter Thiel, it's unsurprising that AtaiBeckley (ATAI -3.29%) ranks as one of the biggest biotech stocks focused on psychedelic drugs. The company was created in 2025 by merging Beckley Psytech and atai Life Sciences, which was founded in 2018 and went public in June 2021. AtaiBeckley has also acquired or made significant strategic investments in several other psychedelic companies.

AtaiBeckley's pipeline features three programs in clinical testing. The company plans to advance BPL-003 into Phase 3 testing for treatment-resistant depression (TRD) after reporting positive Phase 2 results in November 2025. It announced positive top-line results from a Phase 2 study of EMP-01 for the treatment of social anxiety disorder in the first quarter of 2026. AtaiBeckley also expects to announce top-line results from a Phase 2 study of VLS-01 for TRD in the second half of 2026.

The company's Perception Neuroscience unit teamed up with Japanese drugmaker Otsuka (OTC:OTSK.Y) to develop R-ketamine for treating depression. It's the first major collaboration between a psychedelic-focused biotech and a big pharma company. AtaiBeckley is also a major shareholder in Compass Pathways, the next psychedelic drugmaker we'll look at in this list.

2. Compass Pathways

Loading paragraph...

NASDAQ: CMPS

Compass Pathways Plc

Today's Change

(-5.41%) $-0.50

Current Price

$8.75

Key Data Points

Market Cap

$841M

Day's Range

$8.11 - $9.35

52wk Range

$2.25 - $10.21

Volume

Avg Vol

3.8M

Loading company_card...

Compass Pathways (CMPS -5.41%) dates back to 2015, when George Goldsmith and Ekaterina Malievskaia founded the nonprofit organization Compass Trust Limited to support the research and development of psilocybin therapy for individuals with end-of-life anxiety.

Their efforts led to Compass Pathways becoming a for-profit company the following year. In September 2020, the company listed its shares on the Nasdaq stock exchange.

The drugmaker is currently evaluating COMP360 in treatment-resistant depression (TRD) in two Phase 3 studies. It reported positive results from the first of those studies in June 2025. Compass expects to report results from the other late-stage study in 2026.

COMP360 is currently Compass Pathways' only pipeline candidate. However, the company is evaluating the psychedelic therapy as a treatment for two indications other than TRD: post-traumatic stress disorder (PTSD) and anorexia nervosa. Compass Pathways received a green light from the U.S. Food and Drug Administration in January 2026 to advance COMP360 into late-stage testing for PTSD.

3. Helus Pharma

Loading paragraph...

NASDAQ: HELP

Cybin

Today's Change

(17.04%) $0.84

Current Price

$5.77

Key Data Points

Market Cap

$289M

Day's Range

$4.99 - $5.95

52wk Range

$4.29 - $9.83

Volume

2.2K

Avg Vol

Loading company_card...

Loading paragraph...

NASDAQ: DFTX

Definium Therapeutics

Today's Change

(-3.19%) $-0.76

Current Price

$23.08

Key Data Points

Market Cap

$2.3B

Day's Range

$22.62 - $24.15

52wk Range

$6.03 - $26.25

Volume

1.2K

Avg Vol

1.8M

Loading company_card...

Mind Medicine (also known as MindMed) was the first psychedelic drugmaker to conduct an initial public offering (IPO) on Canada's NEO Exchange in March 2020. The company was founded less than a year earlier, in May 2019.

In January 2026, MindMed announced a rebranding as Definium Therapeutics (DFTX -3.19%). The company also changed its stock ticker to DFTX, reflecting its new name.

Definium is evaluating its experimental psychedelic drug DT120 (formerly known as MM120) in two Phase 3 clinical studies targeting generalized anxiety disorder. The company plans to announce results from one of these studies in the first half of 2026, with results from the other study expected in the second half of 2026.

In addition, Definium is evaluating DT120 in another Phase 3 study for major depressive disorder and plans to initiate a second Phase 3 study in the same indication in mid-2026. The company is also evaluating DT402 (formerly known as MM402) in a phase 1 study targeting autism spectrum disorder.

5. GH Research

Loading paragraph...

NASDAQ: GHRS

GH Research

Today's Change

(-8.23%) $-1.70

Current Price

$18.95

Key Data Points

Market Cap

$1.2B

Day's Range

$18.79 - $22.00

52wk Range

$8.75 - $24.66

Volume

392

Avg Vol

220K

Loading company_card...

Loading paragraph...

Investing in psychedelic stocks: FAQ

Loading faq...

About the Author

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

TMFFishBiz

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Best Psychedelic Stocks to Buy in 2026 and How to Invest

Key Points

Key Data Points

2. Compass Pathways

Key Data Points

3. Helus Pharma

Key Data Points

Key Data Points

5. GH Research

Key Data Points

Related investing articles

5 Best Artificial Intelligence (AI) ETFs to Buy in 2026

Best Growth Stocks to Buy in 2026

Best Marijuana Stocks for 2026 and How to Invest

Best Biotech ETFs to Buy in 2026

Investing in psychedelic stocks: FAQ

What are the best psychedelic stocks to buy?

What are the best psychedelic stocks to buy?

Are psychedelic stocks a good investment?

Are psychedelic stocks a good investment?

What is the forecast for psychedelic stocks?

What is the forecast for psychedelic stocks?

Are psychedelic stocks legal to invest in?

Are psychedelic stocks legal to invest in?

What drives growth in psychedelic stocks?

What drives growth in psychedelic stocks?

Is there an ETF for psychedelics?

Is there an ETF for psychedelics?

About the Author

Read Next

Stocks Mentioned

Premium Investing Services

Investing in psychedelic stocks: FAQ

What are the best psychedelic stocks to buy?

What are the best psychedelic stocks to buy?

Are psychedelic stocks a good investment?

Are psychedelic stocks a good investment?

What is the forecast for psychedelic stocks?

What is the forecast for psychedelic stocks?

Are psychedelic stocks legal to invest in?

Are psychedelic stocks legal to invest in?

What drives growth in psychedelic stocks?

What drives growth in psychedelic stocks?

Is there an ETF for psychedelics?

Is there an ETF for psychedelics?

Five top psychedelic stocks for 2026

5 Best Artificial Intelligence (AI) ETFs to Buy in 2026

Best Growth Stocks to Buy in 2026

Best Marijuana Stocks for 2026 and How to Invest

Best Biotech ETFs to Buy in 2026

Key Data Points

1. AtaiBeckley

Benefits and risks of investing in psychedelic stocks

Should you invest in psychedelic stocks?

Related investing articles

FAQ

Key Data Points

Key Data Points

Key Data Points

Key Data Points

3. Helus Pharma

4. Definium Therapeutics

5. GH Research

How to buy psychedelic stocks

2. Compass Pathways